Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2014) 35 P800 | DOI: 10.1530/endoabs.35.P800

ECE2014 Poster Presentations Paediatric endocrinology (33 abstracts)

Small for gestational age (SGA) children: Results after 3 years of GH therapy

Corina Galesanu 1 , Andra Loghin 1 , Ilinka Grozavu 1 , Adrian Condrea 1 & Didona Ungureanu 2


1Endocrinology Department, University of Medicine and Pharmacy ‘Gr.T.Popa’, Iasi, Romania; 2Biochemistry Department, University of Medicine and Pharmacy ‘Gr.T.Popa’, Iasi, Romania.


Introduction: GH therapy (rhGH) improves growth outcome in children born small for gestational age (SGA). Growth velocity is maximum in the first year of therapy. Early diagnosis and treatment optimizes the final height.

Objectives: Evaluation of efficacy and safety profile in the first 3 years of rhGH treatment in ten SGA children.

Methods: The study enrolled ten SGA children (6 boys, 4 girls). All patients were given a mean dose of 0.034 mg/kg/d and followed for a period of minimum 3 years (mean 4.32 years).

Results: The mean height expressed in standards deviations (S.D.) raised from −2.43 at diagnosis to −0.68 after 3 years (Table 1); this achievement declined in time.

In the first 3 years of therapy there were no cases of diabetes mellitus or impaired glucose tolerance (>140<200 mg/dl), one patient (10%) presented impaired fasting glucose (>100<126 mg/dl), one patient (10%) developed hypothyroidism and four patients (40%) presented subclinical hypothyroidism treated with L-thyroxin. No malignancies were observed to date.

Table 1 Data from the first 3 years of rhGH therapy
ParameterBaseline1yr2ys3ys
Chronological age (years)6.297.298.299.29
Bone age (years)4.054.755.567.15
Mean IGF1 values (ng/ml and S.D.)77.5 (+0.24)305.38 (+1.49)258.71 (+1.54)329.85 (+1.26)
Height (S.D.)−2.43−1.37−0.91−0.68
Growth velocity (cm/month)0.980.770.6
Weight (S.D.)−2.3−0.9−0.3−0.52

Conclusions: Growth hormone therapy significantly improves growth in children born SGA, with a favorable safety profile. Maximum height velocity was registered in the first year of treatment, 11.76 cm/year; in the second and third year height velocity declined to 9.24 cm/year and 7.2 cm/year respectively. There were no severe side effects.

Article tools

My recent searches

No recent searches.